Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

Journal of Hepatology

Volumn 53, Issue 5, 2010, Pages 934-940

  Li, Huating ^a,b,c,d   Fang, Qichen ^a,b,c   Gao, Fei ^a,b,c   Fan, Jia ^e   Zhou, Jian ^e   Wang, Xiaoying ^e   Zhang, Huizhen ^a   Pan, Xiaoping ^a,b,c   Bao, Yuqian ^a,b,c   Xiang, Kunsan ^a,b,c   Xu, Aimin ^f   Jia, Weiping ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Diabetes Institute   (China)

^c Shanghai Clinical Center of Diabetes   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e FUDAN UNIVERSITY   (China)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

FGF21; NAFLD; Triglyceride

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 21; MESSENGER RNA; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; LIPID METABOLISM; LIVER LEVEL; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; FATTY LIVER; FEMALE; FIBROBLAST GROWTH FACTORS; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; MALE; MIDDLE AGED; PPAR ALPHA; RNA, MESSENGER; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 77957359658     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.05.018     Document Type: Article

References (31)

1. N. Itoh, and D.M. Ornitz Evolution of the Fgf and Fgfr gene families Trends Gent 20 2004 563 569
2. A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, and E.J. Galbreath FGF21 as a novel metabolic regulator J Clin Invest 115 2005 1627 1635
3. S. Fukumoto Actions and mode of actions of FGF-19 subfamily members Endocr J 55 2008 23 31
4. L.D. Quarles FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization Am J Physiol Endocrinol Metab 285 2003 E1 E9
5. T. Nishimura, Y. Nakatake, M. Konishi, and N. Itoh Identification of a novel FGF, FGF21, preferentially expressed in the liver Biochim Biophys Acta 1492 2000 203 206
6. A. Kharitonenkov, V.J. Wroblewski, A. Koester, Y.F. Chen, C.K. Clutinger, and X.T. Tigno The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 Endocrinology 148 2007 774 781
7. T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, and Y. Chen FGF21 corrects obesity in mice Endocrinology 149 2008 6018 6027
8. T. Uebanso, Y. Taketani, M. Fukaya, K. Sato, Y. Takei, and T. Sato Hypocaloric high-protein diet improves fatty liver and hypertriglyceridemia in sucrose-fed obese rats via two pathways Am J Physiol Endocrinol Metab 297 2009 E76 E84
9. T. Inagaki, P. Dutchak, G. Zhao, X. Ding, L. Gautron, and V. Parameswara Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21 Cell Metab 5 2007 415 425
10. M.L. Reitman FGF21: a missing link in the biology of fasting Cell Metab 5 2007 405 407
11. C. Christodoulides, P. Dyson, D. Sprecher, K. Tsintzas, and F. Karpe Circulating FGF21 is induced by PPAR agonists but not ketosis in Man J Clin Endocrinol Metab 94 2009 3594 3601
12. X. Zhang, D.C. Yeung, M. Karpisek, D. Stejskal, Z.G. Zhou, and F. Liu Serum FGF21 levels are increased in obesity and are independently associated with metabolic syndrome in humans Diabetes 57 2008 1246 1253
13. C. Gälman, T. Lundsen, A. Kharitonenkov, H.A. Bina, M. Eriksson, and I. Hafström The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man Cell Metab 8 2008 169 174
14. H. Li, Y. Bao, A. Xu, X. Pan, J. Lu, and H. Wu Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma- glutamyltransferase but not insulin sensitivity in Chinese subjects J Clin Endocrinol Metab 94 2009 2151 2156
15. A.O. Chavez, M. Molina-Carrion, M.A. Abdul-Ghani, F. Folli, R.A. Defronzo, and D. Tripathy Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance Diabetes Care 32 2009 1542 1546
16. S. Bellentani, and M. Marino Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD) Ann Hepatol 8 2009 S4 S8
17. G. Celle, V. Savarino, A. Picciotto, M.R. Magnolia, P. Scalabrini, and M. Dodero Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques Dig Dis Sci 33 1988 467 471
18. B. Palmentieri, I. de Sio, V. La Mura, M. Masarone, R. Vecchione, and S. Bruno The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis Dig Liver Dis 38 2006 485 489
19. L.S. Szczepaniak, P. Nurenberg, D. Leonard, J.D. Browning, J.S. Reingold, and S. Grundy Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population Am J Physiol Endocrinol Metab 288 2005 E462 E468
20. C.P. Day, and O.F. James Steatohepatitis: a tale of two ''hits''? Gastroenterology 114 1998 842 845
21. S. Chitturi, G.C. Farrell, E. Hashimoto, T. Saibara, G.K. Lau, and J.D. Sollano Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines J Gastroenterol Hepatol 22 6 2007 778 787 (Pubitemid 46915352)
22. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, and O.W. Cummings Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321
23. J. Folch, M. Loes, and S. Stanley A simple method for isolation and purification of total lipids from animal tissues J Biol Chem 226 1957 495 509
24. G. Bucolo, and H. David Quantitative determination of serum triglycerides by the use of enzymes Clin Chem 19 1973 476 482
25. P. Arner, A. Pettersson, P.J. Mitchell, J.D. Dunbar, A. Kharitonenkov, and M. Ryden FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity FEBS Lett 582 2008 1725 1730
26. W. Wente, A.M. Efanov, M. Brenner, A. Kharitonenkov, A. Köster, and G.E. Sandusky Fibroblast growth factor-21 improves pancreatic β-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways Diabetes 55 2006 2470 2478
27. K. Mai, J. Andres, K. Biedasek, J. Weicht, T. Bobbert, and M. Sabath Free fatty acids link metabolism and regulation of the insulin-sensitizing Fibroblast Growth Factor-21 Diabetes 58 2009 1532 1538
28. E. Fabbrini, D. deHaseth, S. Deivanayagam, B.S. Mohammed, B.E. Vitola, and S. Klein Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content Obesity (Silver Spring) 17 2009 25 29
29. Y. Zhang, and P.J. Scarpace The role of leptin in leptin resistance and obesity Physiol Behav 88 2006 249 256
30. E.D. Berglund, C.Y. Li, H.A. Bina, S.E. Lynes, M.D. Michael, and A.B. Shanafelt Fibroblast Growth Factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity Endocrinology 150 2009 4084 4093
31. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010 Aug;139(2):456-63. Epub 2010 May 5.